shares are likely to attract attention early Tuesday after the company Monday said it had won regulatory approval for a test that detects the most common sexually transmitted disease.
After markets closed Monday, the San Diego-based company said the Food and Drug Administration had approved its APTIMA assay for Chlamydia Trachomatis -- an amplified nucleic acid test that detects, on a standalone basis, the bacterium that causes the disease.
"We are now the only company that can offer customers two nucleic acid tests that detect different parts of the CT genome."
Gen-Probe says the APTIMA assay can detect Chlamydia Trachomatis from the widest variety of sample types.
Shares closed at $45.51 Monday.